Inhibikase Therapeutics (IKT) investor relations material

Executive summary

• Advanced IKT-001, a prodrug of imatinib, toward a Phase 2b trial for pulmonary arterial hypertension (PAH) set to begin in Q4 2025; Parkinson's program discontinued and outlicensed.

• Completed CorHepta Pharmaceuticals acquisition, resulting in a $7.4M non-cash R&D charge and $1.8M in stock-based compensation expense.

• Raised $110M in October 2024 private placement, with potential for up to $275M upon full warrant exercise, to fund clinical development and operations.

• Appointed Timothy Pigot as Chief Commercial and Strategy Officer.

• Scheduled to present at the Jefferies Global Healthcare Conference in November 2025.

Financial highlights

• Net loss for Q3 2025 was $11.9M ($0.13/share), compared to $5.8M ($0.65/share) in Q3 2024; nine-month net loss was $35.5M ($0.40/share), up from $15.4M ($2.03/share) year-over-year.

• Research and development expenses rose 82.6% year-over-year to $7.6M for Q3 and 133.9% to $23.4M for the nine months, driven by PAH program and CorHepta acquisition costs.

• Selling, general and administrative expenses increased 242.7% to $5.6M for Q3 and 197.3% to $16.8M for the nine months, including $1.0M in severance costs.

• Cash, cash equivalents, and marketable securities totaled $77.3M as of September 30, 2025, down from $97.5M at December 31, 2024.

• Interest income increased to $838K for Q3 and $2.7M for the nine months, reflecting higher cash balances.

Outlook and guidance

• Cash runway expected to fund operations for at least the next twelve months from September 30, 2025.

• Phase 2b IMPROVE-PAH trial for IKT-001 in PAH is expected to begin in Q4 2025, with interim safety review after 12 weeks for at least 50 patients.

• Anticipates continued increase in R&D and operating expenses as clinical programs advance.

• No revenue expected until regulatory approval and commercialization of product candidates.

• Forward-looking statements highlight risks related to trial commencement and execution.